{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:40:34Z","timestamp":1787161234427,"version":"build-2736575974"},"reference-count":15,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6,1]]},"abstract":"Abstract<\/jats:title>\n Context: Hypoparathyroidism is among the few hormonal insufficiency states not treated with replacement of the missing hormone. This is the first randomized controlled study in children comparing treatment with synthetic human PTH 1-34 and calcitriol.<\/jats:p>\n Objective: The primary objective was to assess the efficacy and safety of long-term PTH 1-34 vs. calcitriol treatment in the maintenance of normal serum calcium values and renal calcium excretion in children with hypoparathyroidism.<\/jats:p>\n Setting: The study was conducted at a clinical research center.<\/jats:p>\n Subjects: Subjects included 12 children aged 5\u201314 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.<\/jats:p>\n Study Design: The study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. sc PTH 1-34 treatment, with weekly or biweekly monitoring of serum and urine calcium.<\/jats:p>\n Results: Mean predose serum calcium levels were maintained at, or just below, the normal range, and urine calcium levels remained in the normal range throughout the 3-yr study, with no significant differences between treatment groups. Creatinine clearance, corrected for body surface area, did not differ between groups and remained normal throughout the study. Markers of bone turnover were mildly elevated during PTH 1-34 therapy and remained within the normal range during calcitriol therapy. Mean bone mineral density Z-scores at the anterior-posterior lumbar spine, femoral neck, distal radius, and whole body remained within the normal range and did not differ between groups throughout the study. Similarly, height and weight percentiles did not differ between treatment groups and remained normal throughout the 3-yr follow-up.<\/jats:p>\n Conclusion: We conclude that PTH 1-34 therapy is safe and effective in maintaining stable calcium homeostasis in children with hypoparathyroidism. Additionally, PTH 1-34 treatment allowed normal skeletal development because there were no differences in bone mineral accrual, linear growth, or weight gain between the two treatment arms over the 3-yr study period.<\/jats:p>","DOI":"10.1210\/jc.2009-2464","type":"journal-article","created":{"date-parts":[[2010,4,14]],"date-time":"2010-04-14T21:35:36Z","timestamp":1271280936000},"page":"2680-2688","source":"Crossref","is-referenced-by-count":141,"title":["Long-Term Treatment of 12 Children with Chronic Hypoparathyroidism: A Randomized Trial Comparing Synthetic Human Parathyroid Hormone 1-34 versus Calcitriol and Calcium"],"prefix":"10.1210","volume":"95","author":[{"given":"Karen K.","family":"Winer","sequence":"first","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-7510"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninet","family":"Sinaii","sequence":"first","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-7510"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Reynolds","sequence":"first","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-7510"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Peterson","sequence":"first","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-7510"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dowdy","sequence":"first","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-7510"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Gordon B.","family":"Cutler","sequence":"first","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-7510"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613122354500_R1","first-page":"273","volume":"9","author":"Weber","journal-title":"Child Nephrol Urol"},{"key":"2020071613122354500_R2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpedi.1986.02140160057032","article-title":"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D)","volume":"140","author":"Santos","year":"1986","journal-title":"Am J Dis Child"},{"key":"2020071613122354500_R3","first-page":"141","article-title":"First experiences in the substitution treatment of hypoparathyroidism with synthetic human parathyroid hormone","volume":"138","author":"Stro\u0308gmann","year":"1990","journal-title":"Monatsschr Kinderheilkd"},{"key":"2020071613122354500_R4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"key":"2020071613122354500_R5","first-page":"3480","article-title":"A randomized, crossover trial of once-daily vs twice-daily human parathyroid hormone 1-34 in the treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613122354500_R6","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613122354500_R7","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1172\/JCI110372","article-title":"Short-term effects of synthetic human parathyroid hormone 1-34 administration on bone mineral metabolism in osteoporotic patients","volume":"68","author":"Slovik","year":"1981","journal-title":"J Clin Invest"},{"key":"2020071613122354500_R8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jbmr.5650010411","article-title":"Restoration of spinal bone in osteoporotic men by treatment with parathyroid hormone 1-34 and 1,25 dihydroxyvitamin D","volume":"1","author":"Slovik","year":"1986","journal-title":"J Bone Miner Res"},{"key":"2020071613122354500_R9","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N Engl J Med"},{"key":"2020071613122354500_R10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone 1-34 on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2020071613122354500_R11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"2020071613122354500_R12","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613122354500_R13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/hmg\/5.5.601","article-title":"Mutations in the Ca-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism","volume":"5","author":"Baron","year":"1996","journal-title":"Hum Mol Genet"},{"key":"2020071613122354500_R14","first-page":"1","article-title":"2000 CDC Growth Charts for the United States: methods and development","volume":"246","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat"},{"key":"2020071613122354500_R15","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1210\/jc.2006-2553","article-title":"The bone mineral density in childhood study (BMDCS): bone mineral content and density according to age, sex, and race","volume":"92","author":"Kalkwarf","year":"2007","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/95\/6\/2680\/9067321\/jcem2680.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/95\/6\/2680\/9067321\/jcem2680.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T19:21:20Z","timestamp":1594927280000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/95\/6\/2680\/2598255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,1]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2009-2464","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.3231958.2916056","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,1]]}}}